TRPC ion channel inhibitors for use in therapy

US12053475B2 · kind B2 · utility

Assignee

• University of Leeds · GB

Inventors

• David John BEECH · Leeds, GB
• Richard J. Foster · Leeds, GB
• Sin Ying CHEUNG · Stanford, US
• Baptiste Michel RODE · Bordeaux, FR

Key dates

• Filing date: Oct 15, 2021
• Grant date: Aug 6, 2024
• Expiry date: May 2, 2042

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/52
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Described herein are inhibitors Transient Receptor Potential Canonical (TRPC) ion channels comprising TRPC4 protein and/or TRPC5 protein for use in combating obesity and other medical conditions including insulin resistance associated with Type II diabetes or development of Type II diabetes (pre-diabetes), metabolic syndrome, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Also disclosed is the use of the inhibitors for cosmetic purposes, such as cosmetic weight loss.